Neurocrine Biosciences, Inc.
NBIX
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.71B
Close$
$431.82
176.5% upside
Current Fair Value
176.5% upsideUndervalued by 176.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.71 Billion |
|---|---|
| Enterprise Value | $16.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $4.81 |
| Beta | 0.38 |
| Outstanding Shares | 101,000,000 |
Return
| Return on Equity | 17.68% |
|---|---|
| Return on Assets | 13.16% |
| Return on Invested Capital | 17.56% |
Valuation & Multiples
| P/E Ratio | 22.16 |
|---|---|
| PEG | 64.55 |
| Price to Sales | 4.73 |
| Price to Book Ratio | 4.0 |
| Enterprise Value to Revenue | 4.77 |
| Enterprise Value to EBIT | 20.46 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$1.65
Average shareholder expectationRevenue Estimate
$891.16 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$2.59
Average shareholder expectationRevenue Estimate
$1.04 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0323▼ 101.61% |
|---|---|
| Total Calls | 408,600▲ 99.90% |
| Total Puts | 421,800▲ 0.74% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 100.94%▲ 1.27% |
|---|---|
| Total Invested | $17.16B▲ 30.25% |
| Investors Holding | 794▲ 75.00% |
ESG Score
No data
About Neurocrine Biosciences, Inc.
CEO: Kevin Gorman